AssayIndex
Incretin analogues and co-agonists

Survodutide

BI 456906 · glucagon/GLP-1 dual agonist · C220H340N50O67 · monoisotopic 4764.5121 Da. The index holds 68 assay reports on this compound across 11 batches from 9 suppliers.

68 reports11 batchesmedian 98.69 %index spec 96.5 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Survodutide sits within 0.3 min of tirzepatide on RG-2, and the index has three confirmed cases of a lot submitted as one and identified by mass as the other. That is why the LC-MS identity module is mandatory for every incretin submission and why a report with purity but no identity confirmation is capped at "unverified" status here. The diagnostic mass is 4764.51 monoisotopic; the 46 Da separation from tirzepatide is trivially resolved at 4+ (m/z 1192.14 vs 1203.61). Purity distribution is wide and n is moderate (under 200), so quarterly medians move materially with a handful of new submissions.

Molecular formula
C220H340N50O67
Monoisotopic mass
4764.5121Da
Average mass
4767.40Da
Residues
39
Nominal retention (RG-2, 30 min)
20.14min
Retention window
0.50min
Counter-ion as usually shipped
TFA
Typical label claims
5 mg · 10 mg · 15 mg
Analytical difficulty (index scale)
1.45 — hard
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

01323264739705293 Survodutide20.14 min · 98.69 % 19.8821.5824.19 same trace · ×100 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Survodutide trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 98.69 % area at the nominal retention time of 20.14 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 68 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 98.69% n=68
Interquartile range 1.06pp n=68
Minimum 97.37% n=68
Maximum 99.89% n=68
Pass rate vs spec 100.0% n=68
Median recovery vs claim 99.0% n=47
Median water 4.80% n=68
Median |mass error| 3.2ppm n=58
0481292.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=497.50–97.75 %: n=397.75–98.00 %: n=998.00–98.25 %: n=398.25–98.50 %: n=798.50–98.75 %: n=1198.75–99.00 %: n=699.00–99.25 %: n=1199.25–99.50 %: n=699.50–99.75 %: n=699.75–100.00 %: n=2median 98.69 Purity (% area) Reports
Figure 2. Purity distribution across all 68 Survodutide records. Dashed line is this compound's median (98.69 %); the solid vertical is the index acceptance specification for the incretin analogues and co-agonists class (96.5 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

97.297.798.198.699.199.6100.1WWBWWB: Q1 98.70, median 99.06, Q3 99.26, n=13n=13TFCTFC: Q1 98.57, median 98.97, Q3 99.15, n=13n=13HomopeptideHomopeptide: Q1 99.22, median 99.57, Q3 99.58, n=9n=9MKMMKM: Q1 97.75, median 97.90, Q3 97.95, n=8outlier 97.44outlier 98.62n=8QSCQSC: Q1 98.78, median 98.97, Q3 99.28, n=7n=7WXTWXT: Q1 97.71, median 98.02, Q3 98.28, n=6n=6GGPepsGGPeps: Q1 97.45, median 97.74, Q3 97.83, n=5n=5ERPERP: Q1 97.99, median 98.13, Q3 98.37, n=4n=4QYBQYB: Q1 98.55, median 98.61, Q3 98.84, n=3n=3 Purity (% area)
Figure 3. Survodutide purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
des-γGlu linker (−129 Da)-0.95-129.04399%0.111.33
[D-Ser2]-diastereomer-0.26mass-identical97%0.361.82
truncated (2-39)-1.36-137.05993%0.110.84
C18 diacid mono-ester+1.44+14.01693%0.050.47
survodutide dimer+4.05+4764.51284%0.040.97
aspartimide (−18 Da)+0.62-18.01174%0.181.62

Degradation pathways

  • aspartimide/β-Asp isomerisation at Asp15-Ser16
  • lipid-tail ester hydrolysis in aqueous storage

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Survodutide phase 2 results in metabolic dysfunction-associated steatohepatitis were reported in NEJM (2024); obesity phase 3 is ongoing.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q30n<3—
2024-Q42099.2498.56–99.89
2025-Q11398.9798.12–99.60
2025-Q21497.9097.37–98.62
2025-Q3398.6198.49–99.06
2025-Q4698.9398.41–99.37
2026-Q1399.0698.61–99.67
2026-Q2597.7497.37–97.90
2026-Q3498.1397.92–98.73

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Survodutide records of 68.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-042547ERPERP-2605-E7682PeptideMeter2026-Q398.255.4493.0Supplier-supplied1MARGINAL
AX-2026-042548ERPERP-2605-E7682Janoshik2026-Q397.925.9692.8Supplier-supplied1MARGINAL
AX-2026-042546ERPERP-2605-E7682Janoshik2026-Q398.015.78105.0Supplier-supplied1MARGINAL
AX-2026-042549ERPERP-2605-E7682Janoshik2026-Q398.735.5191.2Supplier-supplied1MARGINAL
AX-2026-042728GGPepsGGPE-2512-Y9921PeptideMeter2026-Q297.834.1298.6Supplier-supplied1MARGINAL
AX-2026-042730GGPepsGGPE-2512-Y9921PeptideMeter2026-Q297.743.68—Supplier-supplied1MARGINAL
AX-2026-042729GGPepsGGPE-2512-Y9921Janoshik2026-Q297.373.5199.0Laboratory-retained1MARGINAL
AX-2026-042727GGPepsGGPE-2512-Y9921Nordanalyt2026-Q297.453.38—Supplier-supplied1MARGINAL
AX-2026-042731GGPepsGGPE-2512-Y9921Medutest2026-Q297.903.68—Supplier-supplied1MARGINAL
AX-2026-041254WWBWWB-2510-R2141VendorInvestigate2026-Q199.065.79106.9Buyer-sourced1MARGINAL
AX-2026-041702QSCQSC-2509-E9456Kestrel2026-Q199.676.1899.1Laboratory-retained2MARGINAL
AX-2026-041255WWBWWB-2510-R2141Janoshik2026-Q198.615.7491.2Supplier-supplied1MARGINAL
AX-2025-018773QSCQSC-2506-B8101PeptideMeter2025-Q498.896.12102.2Supplier-supplied1MARGINAL
AX-2025-018772QSCQSC-2506-B8101Janoshik2025-Q498.676.31105.8Supplier-supplied1MARGINAL
AX-2025-018774QSCQSC-2506-B8101Janoshik2025-Q498.976.55—Supplier-supplied1MARGINAL
AX-2025-018775QSCQSC-2506-B8101Kestrel2025-Q499.375.9792.9Supplier-supplied1MARGINAL
AX-2025-018776QSCQSC-2506-B8101PeptideMeter2025-Q499.196.07—Supplier-supplied1MARGINAL
AX-2025-018777QSCQSC-2506-B8101Nordanalyt2025-Q498.415.6091.3Supplier-supplied1MARGINAL
AX-2025-018690QYBQYB-2502-G6252VendorInvestigate2025-Q398.495.89103.5Buyer-sourced1MARGINAL
AX-2025-018692QYBQYB-2502-G6252Janoshik2025-Q399.066.19—Supplier-supplied1MARGINAL
AX-2025-018691QYBQYB-2502-G6252Janoshik2025-Q398.615.78103.6Supplier-supplied1MARGINAL
AX-2025-020322MKMMKM-2411-E3058Janoshik2025-Q298.624.8791.4Supplier-supplied1MARGINAL
AX-2025-020317MKMMKM-2411-E3058PeptideMeter2025-Q297.883.91—Supplier-supplied1MARGINAL
AX-2025-021036WXTWXT-2501-X3943Janoshik2025-Q298.304.1490.3Supplier-supplied1MARGINAL
AX-2025-020323MKMMKM-2411-E3058PeptideMeter2025-Q297.944.0889.6Supplier-supplied2MARGINAL